SSTR2 and neoplasm: Thereafter, a few studies which only included a minor amount of NET patients (pNETs as well as GI-NETs were included) showed that SSTR2 antagonists with radiolabeling, i.e., 111In-DOTA-BASS and 68Ga-OPS202 (68Ga-NODAGA-JR11), demonstrated more superior imaging of the tumor and higher sensitivity than SSTR2 agonists with radiolabeling (28, 133–136).